REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 251.15 Billion KRW | 6.0% |
| 2022 | 236.92 Billion KRW | 1.8% |
| 2021 | 232.74 Billion KRW | 165.93% |
| 2020 | 87.52 Billion KRW | 67.69% |
| 2019 | 52.19 Billion KRW | -32.9% |
| 2018 | 77.77 Billion KRW | 9.27% |
| 2017 | 71.17 Billion KRW | 133.83% |
| 2016 | 30.44 Billion KRW | -29.38% |
| 2015 | 43.1 Billion KRW | 20.6% |
| 2014 | 35.73 Billion KRW | -5.96% |
| 2013 | 38 Billion KRW | 24.33% |
| 2012 | 30.56 Billion KRW | 6.39% |
| 2011 | 28.73 Billion KRW | 12.73% |
| 2010 | 25.48 Billion KRW | 15.05% |
| 2009 | 22.15 Billion KRW | -0.83% |
| 2008 | 22.33 Billion KRW | 25.36% |
| 2007 | 17.82 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 248.76 Billion KRW | -0.95% |
| 2024 Q2 | 244.82 Billion KRW | -1.58% |
| 2023 Q1 | 233.46 Billion KRW | -1.46% |
| 2023 FY | 251.15 Billion KRW | 6.0% |
| 2023 Q3 | 249.66 Billion KRW | 0.33% |
| 2023 Q4 | 251.15 Billion KRW | 0.6% |
| 2023 Q2 | 248.85 Billion KRW | 6.59% |
| 2022 Q4 | 236.92 Billion KRW | 2.04% |
| 2022 Q3 | 232.19 Billion KRW | -1.57% |
| 2022 FY | 236.92 Billion KRW | 1.8% |
| 2022 Q1 | 233.68 Billion KRW | 0.41% |
| 2022 Q2 | 235.9 Billion KRW | 0.95% |
| 2021 Q3 | 229.09 Billion KRW | 36.55% |
| 2021 Q2 | 167.77 Billion KRW | 35.86% |
| 2021 FY | 232.74 Billion KRW | 165.93% |
| 2021 Q1 | 123.48 Billion KRW | 41.1% |
| 2021 Q4 | 232.74 Billion KRW | 1.59% |
| 2020 FY | 87.52 Billion KRW | 67.69% |
| 2020 Q1 | 63.38 Billion KRW | 21.45% |
| 2020 Q2 | 66.18 Billion KRW | 4.42% |
| 2020 Q3 | 72.44 Billion KRW | 9.46% |
| 2020 Q4 | 87.52 Billion KRW | 20.8% |
| 2019 Q2 | 61.13 Billion KRW | -31.31% |
| 2019 Q3 | 45.82 Billion KRW | -25.04% |
| 2019 FY | 52.19 Billion KRW | -32.9% |
| 2019 Q4 | 52.19 Billion KRW | 13.9% |
| 2019 Q1 | 88.99 Billion KRW | 14.43% |
| 2018 Q2 | 80.34 Billion KRW | -6.2% |
| 2018 Q1 | 85.64 Billion KRW | 20.33% |
| 2018 Q4 | 77.77 Billion KRW | 7.9% |
| 2018 FY | 77.77 Billion KRW | 9.27% |
| 2018 Q3 | 72.07 Billion KRW | -10.28% |
| 2017 Q3 | 67.85 Billion KRW | 0.0% |
| 2017 FY | 71.17 Billion KRW | 133.83% |
| 2017 Q4 | 71.17 Billion KRW | 4.9% |
| 2017 Q1 | - KRW | -100.0% |
| 2016 Q4 | 30.44 Billion KRW | 0.0% |
| 2016 Q2 | 35.75 Billion KRW | -14.45% |
| 2016 FY | 30.44 Billion KRW | -29.38% |
| 2016 Q1 | 41.79 Billion KRW | -3.03% |
| 2015 Q4 | 43.1 Billion KRW | 22.29% |
| 2015 FY | 43.1 Billion KRW | 20.6% |
| 2015 Q3 | 35.24 Billion KRW | -22.41% |
| 2015 Q2 | 45.42 Billion KRW | 18.4% |
| 2015 Q1 | 38.36 Billion KRW | 7.35% |
| 2014 Q4 | 35.73 Billion KRW | -8.74% |
| 2014 Q3 | 39.16 Billion KRW | 1.75% |
| 2014 Q1 | 39.29 Billion KRW | 3.39% |
| 2014 Q2 | 38.48 Billion KRW | -2.05% |
| 2014 FY | 35.73 Billion KRW | -5.96% |
| 2013 Q1 | 43.58 Billion KRW | 42.57% |
| 2013 Q3 | 39.23 Billion KRW | -8.59% |
| 2013 Q4 | 38 Billion KRW | -3.14% |
| 2013 Q2 | 42.92 Billion KRW | -1.51% |
| 2013 FY | 38 Billion KRW | 24.33% |
| 2012 Q1 | 30.14 Billion KRW | 4.93% |
| 2012 Q3 | 24.16 Billion KRW | -4.49% |
| 2012 Q4 | 30.56 Billion KRW | 26.5% |
| 2012 FY | 30.56 Billion KRW | 6.39% |
| 2012 Q2 | 25.29 Billion KRW | -16.09% |
| 2011 Q2 | 36.53 Billion KRW | -13.21% |
| 2011 Q1 | 42.09 Billion KRW | 65.15% |
| 2011 Q3 | 31.78 Billion KRW | -13.0% |
| 2011 Q4 | 28.73 Billion KRW | -9.59% |
| 2011 FY | 28.73 Billion KRW | 12.73% |
| 2010 Q3 | 23.51 Billion KRW | -8.86% |
| 2010 FY | 25.48 Billion KRW | 15.05% |
| 2010 Q4 | 25.48 Billion KRW | 8.41% |
| 2010 Q2 | 25.79 Billion KRW | 0.0% |
| 2009 FY | 22.15 Billion KRW | -0.83% |
| 2008 FY | 22.33 Billion KRW | 25.36% |
| 2007 FY | 17.82 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -222.576% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 72.989% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 64.481% |
| HANDOK Inc. | 449.7 Billion KRW | 44.152% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -193.16% |
| Yuhan Corporation | 712.33 Billion KRW | 64.743% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 60.255% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -1480.114% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 70.516% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -369.19% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -21.992% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -234.106% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -69.933% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -256.742% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -222.576% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -589.289% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -13.795% |
| JW Holdings Corporation | 827.51 Billion KRW | 69.65% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 42.528% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 57.199% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 33.838% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -216.704% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -258.953% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -3.417% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 23.961% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -222.576% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 48.747% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 70.729% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 33.838% |
| Yuhan Corporation | 712.33 Billion KRW | 64.743% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 47.437% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -83.364% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 51.39% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 33.838% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -62.519% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -179.164% |
| CKD Bio Corp. | 170.76 Billion KRW | -47.078% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -3.043% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -59.302% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -483.812% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -216.704% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 60.294% |
| Boryung Corporation | 373.1 Billion KRW | 32.687% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -20.631% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -21.992% |
| JW Lifescience Corporation | 96.44 Billion KRW | -160.413% |